Products
Sutacimig Biosimilar Bispecific Antibody (Factor VIIa × TLT-1) for Research
Cat No.: GMP-Bios-INN-1402
Anti-F7a/F7A/FVIIa/FVIIA therapeutic antibody (Pre-made Sutacimig biosimilar,Bispecific Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Sutacimig (development code HMB001) is a humanized bispecific monoclonal antibody targeting coagulation factor VII (F7). It is developed by Hemab for Thrombasthenia, Factor VII deficiency in Phase I/II development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1402-1mg | 1mg | |
| GMP-Bios-INN-1402-10mg | 10mg | |
| GMP-Bios-INN-1402-100mg | 100mg | |
| GMP-Bios-INN-1402-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Sutacimig biosimilar, Bispecific Whole mAb, Anti-F7a/F7A/FVIIa/FVIIA;TREML1/GLTL1825/PRO3438/TLT-1/TLT1 Antibody: Anti-TREML1/Trem-like transcript 1 protein/TLT-1/Triggering receptor expressed on myeloid cells-like protein 1 therapeutic antibody |
| INN Name | Sutacimig |
| Target | F7a/F7A/FVIIa/FVIIA;TREML1/GLTL1825/PRO3438/TLT-1/TLT1 |
| Format | Bispecific Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G4;G4 |
| VD LC | Kappa;Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I/II |
| Est. Status | Active |
| 100% SI Structure | 8cn9:BA:GF:LK:QP;8che:HL:AB |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2024 |
| Year Recommended | na |
| Companies | Hemab |
| Conditions Approved | na |
| Conditions Active | Thrombasthenia;Factor VII deficiency |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
